Patient demographics and disease characteristics at baseline
| RA (N = 528) | PsA (N = 205) | Psoriasis (N=583) | |
|---|---|---|---|
| Sex, n (%) | |||
| Men | 141 (27) | 105 (51) | 382 (66) |
| Women | 387 (73) | 100 (49) | 201 (34) |
| Age, mean years (SD) | 51.4 (0.6)* | 47.4 (11.1) | 45.2 (11.9) |
| Range | 18–84 | 18–76 | 18–87 |
| Race/ethnicity, n (%) | |||
| White | 463 (88) | 186 (91) | 528 (91) |
| Black/African-American | 6 (1) | 5 (2) | 8 (1) |
| Hispanic/Latino | 27 (5) | 11 (5) | 19 (3) |
| Other | 32 (6) | 3 (2) | 28 (5) |
| Disease duration, mean | |||
| RA | 9.0 mos | – | – |
| PsA | – | 9.1 yrs | – |
| Psoriasis | – | 19.0 yrs | 20.5 yrs |
| Previous therapies | |||
| n (%) DMARD | 113 (21) | 156 (76) | – |
| Psoriasis therapies | – | 147 (72) | 516 (89) |
| Disease characteristics | |||
| Tender joint count, mean no (SD) | 25.0 (14.5)† | 21.3 (14.3)‡ | – |
| Swollen joint count, mean no (SD) | 17.3 (10.2)§ | 15.6 (10.6)** | – |
| PASI score,†† mean (SD) | – | 10.4 (10.7)‡‡ | 19.1 (8.5) |
| Psoriasis-affected BSA, mean % (SD) | – | 10.6 (15.4) | 28.0 (17.4) |
| Patient-reported outcomes | |||
| HAQ,§§ mean score (SD) | 1.7 (0.7) | 1.1 (0.6) | – |
| DLQI,¶ mean score (SD) | – | – | 11.7 (6.8) |
↵* Data represent mean (standard error) for patients with RA.
↵† 71 possible joints.
↵‡ 78 possible joints.
↵§ 68 possible joints.
↵** 76 possible joints.
↵†† PASI scores range from 0 (no psoriasis) to 72 (severe disease).
↵‡‡ PASI scores were only collected from psoriasis patients with affected BSA ≥3% (n=128).
↵§§ HAQ scores range from 0 to 3.
↵¶ DLQI scores range from 0 (no effect on patient's life) to 30 (extremely large effect on patient's life).
BSA, body surface area; DLQI, dermatology life quality index; DMARD, disease-modifying antirheumatic drug; HAQ, health assessment questionnaire; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; RA, rheumatoid arthritis.